MedAlliance has launched Origin SC and Origin NC, two high performance balloons for vessel preparation, which are complementary to Selution SLR its novel sirolimus-eluting balloon.
Origin SC is a semi-compliant (SC) percutaneous transluminal coronary angioplasty (PTCA) balloon with a low crossing profile, making it an option for challenging lesions. Origin SC comes in a broad portfolio of sizes available for an SC balloon, including 1mm, 1.25mm, 1.5mm and 1.75mm balloon diameters.
Origin NC is a non-compliant (NC) PTCA balloon, combining high pressure tolerance and controlled compliance with an optimal crossing profile for the most challenging cases. Origin NC’s minimal balloon longitudinal growth ensures focused dilatation force on the target lesion, minimising the risk of damaging healthy tissue, MedAlliance said in a press release. Origin NC also offers one of the lowest crossing profiles among all categories of PTCA balloon catheter currently available, the company added, noting that this is particularly appropriate when facing tight stenoses in calcified, fibrotic lesions.
“We are excited to be broadening our balloon portfolio with the Origin range which complements our flagship drug-eluting balloon (DEB) Selution SLR”, said Jeffrey B Jump, chairman and CEO of MedAlliance. “This is just the start of our product expansion program to vertically integrate high quality products for the benefit of patients around the world.”
MedAlliance’s DEB technology involves MicroReservoirs made from biodegradable polymer intermixed with the antirestenotic drug sirolimus. According to MedAlliance, these MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary cell adherent technology (CAT) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon.
Selution SLR was awarded CE mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary arterial disease in May 2020. It is now available in Europe and all other countries where the CE mark is recognised.